Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
20/09/2025
X: The company is taking strong action against a bribery network targeting this platform.
Latest
1 m ago
Nancy Ibach, Vice President of the Oncology Department of Merck USA, stated that their cancer therapy Keytruda, in its new subcutaneous injection form called Keytruda Qlex, can be administered in just one to two minutes, depending on the dosage, while intravenous infusion typically takes about 30 minutes.
1 m ago
Nancy Ibach, Vice President of the Oncology Business Unit of MSD USA, stated that their cancer therapy Keytruda subcutaneous injection new dosage form is branded as Keytruda Qlex. Depending on the dosage, administration can be completed in just one to two minutes, whereas intravenous infusion typically takes about 30 minutes.
2 m ago
The US dollar index rose by 0.3% on Friday, with a V-shaped reversal for the week.
2 m ago
The US FDA has approved Merck's blockbuster cancer therapy Keytruda in subcutaneous injection form. Analysts say this marks a significant change in the dosing method of this globally top-selling cancer immunotherapy, with the potential to improve patient experience and clinical efficiency. This move is also seen as a strategic component of Merck's defense of Keytruda's market share as competition from biosimilars intensifies.
2 m ago
The US FDA has approved Merck's blockbuster cancer therapy Keytruda in subcutaneous injection form. Analysts say this marks a significant change in the way this global best-selling cancer immunotherapy is administered, with the potential to improve patient experience and treatment efficiency. This move is also seen as a strategic component of Merck's defense of Keytruda's market share as competition from biosimilars approaches.
See all latest
